Recently, Shin et al. [111] revised an α-helical (AH-D) peptide with a heightened α-helical structure and the ability to sense highly curved lipid membranes, especially exosomes derived from tumor cells (T-EXOs), and the peptide could target and induce T-EXOs’ rupture and degradation in a pH-enhanced manner associated with the tumor niche, which effectively decreases the exosomal PD-L1 level in the circulation and recovered function of CD8+ T-cells to synergistically enhance cancer immunotherapy. This evidence concerns the gene CD8A and neoplasm.